Gerald Miletello, MD
Medical Oncology · Baton Rouge, LANPI 1245217728
Payments from drug & device makers
Across 1,000 payments — averaging $326.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$148K
- Sanofi US Services Inc.$66K
- Mirati Therapeutics, Inc.$56K
- AstraZeneca$25K
- Pfizer$6K
- Clinigen, Inc.$6K
- plus $20K from 54 others
Across 2 payments — averaging $3556.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
What the payments were for
- Consulting fees$4,92519%
- Speaking & faculty fees$1,6506%
- Food & beverage$18,31771%
- Education$9534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proleukin$5,550
- OPDIVO$369
- BRUKINSA$229
- SIR-Spheres Microspheres$139
- TRINAV INFUSION SYSTEM$127
- Beleodaq$125
- JAKAFI$124
- Axumin$122
- Avastin$100
How this compares
Too few medical oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 133 | $2,035,784 |
| CabometyxCabozantinib S-Malate | 48 | $1,196,471 |
| IbrancePalbociclib | 53 | $838,202 |
| ImbruvicaIbrutinib | 34 | $565,326 |
| NinlaroIxazomib Citrate | 41 | $520,447 |
| XtandiEnzalutamide | 28 | $385,344 |
| PromactaEltrombopag Olamine | 30 | $272,936 |
| BrukinsaZanubrutinib | 16 | $240,536 |
| KisqaliRibociclib Succinate | 14 | $225,593 |
| ZejulaNiraparib Tosylate | 13 | $221,301 |
| Lenalidomide | 13 | $184,627 |
| CalquenceAcalabrutinib Maleate | 13 | $155,384 |
| OrgovyxRelugolix | 45 | $120,080 |
| NubeqaDarolutamide | 12 | $95,502 |
| ZelborafVemurafenib | 12 | $80,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $353 | $2,035,784133 claims |
| Exelixis Inc.Cabometyx | $364 | $1,196,47148 claims |
| PfizerIbrance, Eliquis | $6,371 | $859,87169 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $337 | $565,32634 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $455 | $520,44741 claims |
| NovartisPromacta, Kisqali | $3,055 | $498,52944 claims |
| Astellas Pharma US IncXtandi | $362 | $385,34428 claims |
| Beigene USA, Inc.Brukinsa | $370 | $240,53616 claims |
| GSKZejula | $383 | $221,30113 claims |
| AstraZenecaCalquence | $25,199 | $155,38413 claims |
| BayerNubeqa | $328 | $95,50212 claims |
| Johnson & JohnsonXarelto | $769 | $23,75718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Baton Rouge
- Michael CastineBaton Rouge$2.7M
- Pavani EllipeddiBaton Rouge$13K
- Cody MillimanBaton Rouge$7K
- Constance BluntBaton Rouge$4K
- Laura FinnNew Orleans$1.4M
- Daniel JohnsonNew Orleans$1M
- Agustin GarciaIndependence$140K
- Mark SidesNew Orleans$11K
- Elizabeth LejeuneLafayette$6K
- Joseph BrierreLafayette$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.